Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Biotech’s trade secrets face growing threat from foreign influences, science leaders warn

    June 8, 2023

    Canadian biotech narrows trial population to lift solid tumor drug out of FDA hold

    June 7, 2023

    Biotechs face challenges as the industry’s annual bash returns to Boston

    June 5, 2023
    Facebook Twitter Instagram
    Your Biotech
    • Bio Technology

      Biotech’s trade secrets face growing threat from foreign influences, science leaders warn

      June 8, 2023

      Canadian biotech narrows trial population to lift solid tumor drug out of FDA hold

      June 7, 2023

      Biotechs face challenges as the industry’s annual bash returns to Boston

      June 5, 2023

      The Biotech Buying Bonanza: Why The FTC’s Amgen Battle Won’t Chill The Spree

      June 5, 2023

      China reaching for biotech breakthroughs in space

      June 2, 2023
    • Pharmaceutical

      Pharma company owner duped of ₹1.1 crore

      November 11, 2022

      Novavax cuts full-year revenue forecast again amid weak demand

      November 10, 2022

      Aurobindo units recall products in US market for manufacturing issues

      November 9, 2022

      AASLD 2022 | Ascentage Pharma Releases Phase I Results of IAP Antagonist APG-1387 in an Oral Report Showing Potential for Functionally Curing CHB

      November 8, 2022

      Trade Spotlight | What should you do with Amara Raja, Sun Pharma Advanced Research, Poly Medicure on Monday?

      November 7, 2022
    Your Biotech
    Home»Bio Technology»Axcella Clears Regulatory Path for Long COVID Therapeutic
    Bio Technology

    Axcella Clears Regulatory Path for Long COVID Therapeutic

    yourbiotechBy yourbiotechJanuary 25, 2023Updated:January 25, 2023No Comments3 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp VKontakte Email
    Medical worker wearing personal protective equipment doing corona virus swab on female patient - Covid19 test and health care concept
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Axcella Therapeutics’ Long COVID fatigue therapeutic is moving forward. Monday, the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) gave the company regulatory guidance supporting a single trial for AXA1125.

    The Massachusetts-based biotech has also filed an Investigational New Drug application with the FDA, seeking a Phase IIb/III trial for AXA1125. In an investor call Tuesday morning, Bill Hinshaw, president and CEO of Axcella, said this study is meant to be a “global, integrated trial to achieve registration.”

    According to the regulatory guidance, the MHRA and Axcella were able to align on key trial details, including the primary endpoint and design. 

    Axcella’s efforts to engage both the FDA and MHRA follow the candidate’s promising Phase IIa performance reported in August 2022. In the study, patients treated with AXA1125 saw significant improvements in total, mental, and physical fatigue scores as compared with their placebo counterparts. Moreover, treatment with Axcella’s candidate resulted in a significantly greater distance traveled during the 6-minute walk test, an objective measure of physical ability. AXA1125 is an endogenous metabolic modulator that works by incorporating several amino acids and their derivatives, in specific ratios, to tweak metabolic pathways related to the disease.

    A Lingering Issue

    Long COVID refers to symptoms related to the infection that persist long after the virus has been cleared from the body. It is characterized by a wide and diverse range of symptoms that include excessive fatigue, fever, difficulty breathing, chest pain, headaches, and sleep problems.

    Because the condition is relatively new, the true extent of its effect is still not known. However, long-term COVID affects an estimated 100 million people worldwide, with fatigue being its most common manifestation. In the U.S., Long COVID has forced approximately 1 million people out of work, costing about $1 trillion in lost earnings and $529 billion in medical expenditures.

    Aside from Axcella, several other biotech companies are developing therapies for long-term COVID. Telogen, for instance, is advancing a precision T cell candidate dubbed TVGN-489. In a proof-of-concept trial, none of the coronavirus patients treated with Tevogen’s candidate developed long COVID, pointing to its therapeutic potential, which the company hopes to explore in future studies.

    Joining Axcella and Tevogen is Precision Genomics, which announced in October 2022 that its new mRNA technology could help diagnose COVID and help other companies establish treatment protocols for the condition. The mRNA platform includes a proprietary 48-gene microarray and a planned medical artificial intelligence program to identify genetic patterns linked to inflammation

    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Previous ArticleWHO urges ‘immediate action’ after cough syrup deaths, 3 global medical alerts issued
    Next Article Rising Trends of Biotechnology Separation Systems Market Segments, Graphs, Growth With in-detailed Competitor Analysis, Forecast to 2030
    yourbiotech
    • Website

    Related Posts

    Biotech’s trade secrets face growing threat from foreign influences, science leaders warn

    June 8, 2023

    Canadian biotech narrows trial population to lift solid tumor drug out of FDA hold

    June 7, 2023

    Biotechs face challenges as the industry’s annual bash returns to Boston

    June 5, 2023

    The Biotech Buying Bonanza: Why The FTC’s Amgen Battle Won’t Chill The Spree

    June 5, 2023

    Leave A Reply Cancel Reply

    Our Picks

    Subscribe to Updates

    Get the latest creative news from SmartMag about art & design.

    About Us
    About Us

    We provide a wide range of customized, integrated B2B and B2C digital marketing services solutions that are ideal for your business.

    We're accepting new partnerships right now.

    Email Us: info@yourmartech.com
    Contact: +1-530-518-1420

    Our Brands
    • Your Martech
    • Your HR Tech
    • Your Fin Tech
    • Your Revenue
    • Your Info Tech
    • Your POS Tech
    • Your Health Tech
    SUBSCRIBE NOW
    Loading
    LinkedIn
    • Privacy Policy
    © 2022 Vigarbiz Inc. Designed by Vigarbiz Media

    Type above and press Enter to search. Press Esc to cancel.